Show simple item record

dc.contributor.authorGe, Jin
dc.contributor.authorPletcher, Mark J.
dc.contributor.authorLai, Jennifer C.
dc.contributor.authorN3C Consortium
dc.date2022-08-11T08:11:03.000
dc.date.accessioned2022-08-23T17:29:58Z
dc.date.available2022-08-23T17:29:58Z
dc.date.issued2021-11-01
dc.date.submitted2021-12-21
dc.identifier.citation<p>Ge J, Pletcher MJ, Lai JC; N3C Consortium. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Gastroenterology. 2021 Nov;161(5):1487-1501.e5. doi: 10.1053/j.gastro.2021.07.010. Epub 2021 Jul 18. PMID: 34284037; PMCID: PMC8286237. <a href="https://doi.org/10.1053/j.gastro.2021.07.010">Link to article on publisher's site</a></p>
dc.identifier.issn0016-5085 (Linking)
dc.identifier.doi10.1053/j.gastro.2021.07.010
dc.identifier.pmid34284037
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50436
dc.description<p>The UMass Center for Clinical and Translational Science (UMCCTS), UL1TR001453, helped fund this study.</p> <p>This article is based on a previously available preprint in <a href="https://doi.org/10.1101/2021.06.03.21258312" target="_blank" title="view preprint in medRxiv">medRxiv</a>.</p>
dc.description.abstractBACKGROUND and AIMS: In patients with chronic liver disease (CLD) with or without cirrhosis, existing studies on the outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have limited generalizability. We used the National COVID Cohort Collaborative (N3C), a harmonized electronic health record dataset of 6.4 million, to describe SARS-CoV-2 outcomes in patients with CLD and cirrhosis. METHODS: We identified all patients with CLD with or without cirrhosis who had SARS-CoV-2 testing in the N3C Data Enclave as of July 1, 2021. We used survival analyses to associate SARS-CoV-2 infection, presence of cirrhosis, and clinical factors with the primary outcome of 30-day mortality. RESULTS: We isolated 220,727 patients with CLD and SARS-CoV-2 test status: 128,864 (58%) were noncirrhosis/negative, 29,446 (13%) were noncirrhosis/positive, 53,476 (24%) were cirrhosis/negative, and 8941 (4%) were cirrhosis/positive patients. Thirty-day all-cause mortality rates were 3.9% in cirrhosis/negative and 8.9% in cirrhosis/positive patients. Compared to cirrhosis/negative patients, cirrhosis/positive patients had 2.38 times adjusted hazard of death at 30 days. Compared to noncirrhosis/positive patients, cirrhosis/positive patients had 3.31 times adjusted hazard of death at 30 days. In stratified analyses among patients with cirrhosis with increased age, obesity, and comorbid conditions (ie, diabetes, heart failure, and pulmonary disease), SARS-CoV-2 infection was associated with increased adjusted hazard of death. CONCLUSIONS: In this study of approximately 221,000 nationally representative, diverse, and sex-balanced patients with CLD; we found SARS-CoV-2 infection in patients with cirrhosis was associated with 2.38 times mortality hazard, and the presence of cirrhosis among patients with CLD infected with SARS-CoV-2 was associated with 3.31 times mortality hazard. These results provide an additional impetus for increasing vaccination uptake and further research regarding immune responses to vaccines in patients with severe liver disease.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34284037&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8286237/
dc.subjectCOVID-19
dc.subjectCirrhosis
dc.subjectN3C
dc.subjectOMOP
dc.subjectSARS-CoV-2
dc.subjectUMCCTS funding
dc.subjectDigestive System Diseases
dc.subjectGastroenterology
dc.subjectHepatology
dc.subjectInfectious Disease
dc.subjectTranslational Medical Research
dc.subjectVirus Diseases
dc.titleOutcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study
dc.typeJournal Article
dc.source.journaltitleGastroenterology
dc.source.volume161
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/umccts_pubs/258
dc.identifier.contextkey26928303
html.description.abstract<p>BACKGROUND and AIMS: In patients with chronic liver disease (CLD) with or without cirrhosis, existing studies on the outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have limited generalizability. We used the National COVID Cohort Collaborative (N3C), a harmonized electronic health record dataset of 6.4 million, to describe SARS-CoV-2 outcomes in patients with CLD and cirrhosis.</p> <p>METHODS: We identified all patients with CLD with or without cirrhosis who had SARS-CoV-2 testing in the N3C Data Enclave as of July 1, 2021. We used survival analyses to associate SARS-CoV-2 infection, presence of cirrhosis, and clinical factors with the primary outcome of 30-day mortality.</p> <p>RESULTS: We isolated 220,727 patients with CLD and SARS-CoV-2 test status: 128,864 (58%) were noncirrhosis/negative, 29,446 (13%) were noncirrhosis/positive, 53,476 (24%) were cirrhosis/negative, and 8941 (4%) were cirrhosis/positive patients. Thirty-day all-cause mortality rates were 3.9% in cirrhosis/negative and 8.9% in cirrhosis/positive patients. Compared to cirrhosis/negative patients, cirrhosis/positive patients had 2.38 times adjusted hazard of death at 30 days. Compared to noncirrhosis/positive patients, cirrhosis/positive patients had 3.31 times adjusted hazard of death at 30 days. In stratified analyses among patients with cirrhosis with increased age, obesity, and comorbid conditions (ie, diabetes, heart failure, and pulmonary disease), SARS-CoV-2 infection was associated with increased adjusted hazard of death.</p> <p>CONCLUSIONS: In this study of approximately 221,000 nationally representative, diverse, and sex-balanced patients with CLD; we found SARS-CoV-2 infection in patients with cirrhosis was associated with 2.38 times mortality hazard, and the presence of cirrhosis among patients with CLD infected with SARS-CoV-2 was associated with 3.31 times mortality hazard. These results provide an additional impetus for increasing vaccination uptake and further research regarding immune responses to vaccines in patients with severe liver disease.</p>
dc.identifier.submissionpathumccts_pubs/258
dc.contributor.departmentUMass Center for Clinical and Translational Science
dc.source.pages1487-1501.e5


This item appears in the following Collection(s)

Show simple item record